Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications

交易增加双重BBB递送策略，支持阿尔茨海默病项目、联合疗法、505(b)(2)途径和CNS应对措施应用

SACRAMENTO, Calif.

加利福尼亚州萨克拉门托

,

，

May 4, 2026

2026年5月4日

/PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:

/PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:

LNAI

LNAI

) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies. The acquired portfolio is designed to address a key limitation in neurological disease treatment, including Alzheimer's disease, where the blood-brain barrier (BBB) can restrict therapeutic access to the brain.

）今天宣布完成了一项2000万美元的优先股发行，用于从两家交易对手收购知识产权资产，扩展了公司中枢神经系统（CNS）平台，新增了互补的神经治疗化合物和递送技术。所收购的产品组合旨在解决神经系统疾病治疗中的一个关键限制，包括阿尔茨海默病，其中血脑屏障（BBB）可能限制治疗药物进入大脑。

The expanded intellectual property portfolio introduces complementary CNS delivery technologies and multi-agent, combinatorial therapeutic approaches, which will be integrated into Lunai Bioworks IP, Inc., a wholly owned subsidiary, broadening the Company's growing platform of neurological disease and biodefense applications..

扩充的知识产权组合引入了互补的中枢神经系统递送技术和多药剂、组合治疗方案，这些将被整合到全资子公司Lunai Bioworks IP公司中，从而拓宽公司在神经疾病和生物防御应用领域不断增长的平台。

The transaction integrates two distinct CNS delivery approaches into Lunai's platform: a BBB-crossing prodrug system and a nose-to-brain (N2B) delivery pathway that bypasses the BBB via olfactory and trigeminal routes. Together, these approaches are intended to support both individual and combination therapies, align with Lunai's AI-driven patient stratification strategy, expand potential applications across neurological disease, 505(b)(2) development pathways, and CNS-targeted biodefense and countermeasure programs, and position Lunai for potential partnership, licensing, and non-dilutive funding opportunities..

该交易将两种不同的中枢神经系统递送方法整合到Lunai的平台中：一种是能够穿越血脑屏障的前药系统，另一种是通过嗅觉和三叉神经通路绕过血脑屏障的鼻脑（N2B）递送途径。这两种方法相结合，旨在支持个体化治疗和联合疗法，契合Lunai基于人工智能的患者分层策略，拓展在神经系统疾病、505(b)(2)开发路径、以及针对中枢神经系统的生物防御与应对计划中的潜在应用，并为Lunai带来潜在的合作伙伴关系、许可及非稀释性融资机会。

The acquired intellectual property expands Lunai's ability to connect therapeutic discovery with delivery, supporting a more integrated approach to CNS drug development. By pairing compound design with delivery optimization, the Company is advancing a framework aimed at increasing drug concentration in the brain while reducing systemic exposure.

所收购的知识产权扩大了Lunai将治疗发现与递送相连接的能力，支持一种更综合的中枢神经系统药物开发方法。通过将化合物设计与递送优化相结合，公司正在推进一个旨在提高药物在大脑中的浓度同时减少系统暴露的框架。

This approach addresses both challenges by combining novel neurotherapeutic compounds with complementary delivery technologies, improving CNS access and enabling multi-agent, combinatorial strategies. Together, the portfolio strengthens Lunai's ability not only to deliver therapeutics to the brain, but to develop and deploy both single-agent and combination therapies that target distinct aspects of disease biology.

这种方法通过将新型神经治疗化合物与互补的递送技术相结合，解决了这两个挑战，改善了中枢神经系统的可及性，并实现了多药物组合策略。整体而言，该产品组合不仅增强了Lunai将治疗药物递送到大脑的能力，还加强了其开发和部署针对疾病生物学不同方面的单药和组合疗法的能力。

This approach may be applicable across multiple neurological indications as well as in settings requiring rapid CNS access..

这种方法可能适用于多种神经学指征，也适用于需要快速进入中枢神经系统的场景。

Lunai's Augusta platform is designed to stratify patient populations based on underlying biological drivers rather than traditional disease classifications. The integration of these assets is expected to support the development of targeted therapeutic combinations matched to specific patient subgroups, including in the context of neurological disease and acute toxic or environmental exposures.

Lunai的Augusta平台旨在根据潜在的生物学驱动因素对患者群体进行分层，而非传统的疾病分类。这些资产的整合预计将支持针对特定患者亚群的靶向治疗组合的开发，包括在神经系统疾病和急性毒性或环境暴露的情况下。

This combined approach is intended to improve the efficiency of candidate selection and advancement..

这种综合方法旨在提高候选人选拔和晋升的效率。

The combined platform is also expected to support multiple regulatory pathways, including potential 505(b)(2) opportunities for reformulated or repurposed therapeutics. These pathways may enable more efficient development timelines and reduced clinical risk relative to traditional de novo drug development programs..

该联合平台预计还将支持多种监管路径，包括针对改良或重新利用的治疗药物的潜在505(b)(2)机会。与传统的全新药物开发项目相比，这些路径可能有助于更高效的开发时间表和降低临床风险。

In addition, the expanded intellectual property portfolio is expected to strengthen Lunai's role in biodefense-related initiatives, including its Pathfinder program, by increasing its capacity to evaluate and deploy CNS-targeted countermeasures. This includes the potential use of established pharmacological agents in combination with alternative delivery approaches designed for rapid administration and central nervous system access following chemical or environmental exposures..

此外，扩充的知识产权组合预计将通过提高评估和部署针对中枢神经系统的对策的能力，加强Lunai在生物防御相关计划中的角色，包括其探路者(Pathfinder)计划。这包括潜在使用已确立的药物学制剂结合旨在快速给药和中枢神经系统接触的替代递送方法，以应对化学或环境暴露。

'This transaction brings together complementary CNS delivery approaches that address one of the most persistent challenges in neurological drug development,' said David Weinstein, Chief Executive Officer of Lunai Bioworks. 'By integrating these technologies with our existing platform, we are expanding our ability to develop and deliver targeted therapies, while also opening additional pathways for partnership, licensing, and non-dilutive funding.'.

“这项交易结合了互补的中枢神经系统递送方法，解决了神经药物开发中一个最持久的挑战，”Lunai Bioworks首席执行官David Weinstein表示。“通过将这些技术整合到我们现有的平台中，我们正在扩展开发和提供靶向治疗的能力，同时也为合作伙伴关系、许可和非稀释性融资开辟了更多途径。”

On May 1, 2026, the Company completed the Merger and issued the Series B Preferred Stock having an aggregate Stated Value of $20,000,000 to the Holders. The Merger and the related issuance of the Series B Preferred Stock is the principal transaction undertaken by the Company to achieve compliance with the Nasdaq Stockholders' Equity Rule and the Company will determine and disclose the equity treatment of the Series B Preferred Stock in accordance with applicable accounting standards.

2026年5月1日，公司完成了合并，并向持有人发行了总面值为2亿美元的B系列优先股。此次合并及相关的B系列优先股发行是公司为符合纳斯达克股东权益规则而采取的主要交易，公司将根据适用的会计准则确定并披露B系列优先股的权益处理方式。

After giving effect to the Merger, the issuance of the Series B Preferred Stock, and based on the Company's preliminary accounting and fair-value analysis, the Company believes its stockholders' equity exceeds the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1). The Company is awaiting the Panel's formal determination of compliance with the Stockholder's Equity Rule.

在完成合并、发行B系列优先股，并基于公司的初步会计和公允价值分析后，公司认为其股东权益超过了纳斯达克上市规则5550(b)(1)所要求的250万美元最低限额。公司正在等待专家组对符合股东权益规则的正式确认。

There can be no assurance that the Panel will determine that the Company has satisfied the Stockholders' Equity Rule, and any such determination by the Panel is subject to the Panel's continuing review of the Company's disclosures, financial condition and progress toward compliance with the Bid Price Rule.

无法保证专家组会认定公司已满足股东权益规则，且专家组的任何此类决定均需接受专家组对公司披露、财务状况及遵守投标价格规则进展的持续审查。

If the Panel determines that the Company has not satisfied the conditions set forth in the Panel's decision (as so extended), Nasdaq may take further action to delist the Company's common stock from The Nasdaq Capital Market..

如果专家组确定公司未满足专家组决定（如此延期）中规定的条件，纳斯达克可能会采取进一步行动，将公司的普通股从纳斯达克资本市场摘牌。

About Lunai Bioworks, Inc.

关于Lunai生物工程公司

Lunai Bioworks (NASDAQ:

露娜生物工程公司（纳斯达克：

LNAI

LNAI

) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform. Lunai combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. Lunai is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates..

是一家由人工智能驱动的生物技术公司，通过其集成平台推动药物发现和化学防御。Lunai结合临床数据、机器学习和体内验证来识别疾病生物学并开发精准治疗药物。Lunai专注于中枢神经系统疾病和肿瘤学，致力于缩短开发时间并提高临床成功率。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding the expected benefits of the transaction, potential applications of the acquired intellectual property, development timelines, regulatory pathways, and potential partnership, licensing, or funding opportunities.

本新闻稿包含适用证券法意义上的前瞻性声明。这些声明包括但不限于关于交易的预期收益、所收购知识产权的潜在应用、开发时间表、监管路径以及潜在的合作伙伴关系、许可或融资机会的声明。

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Lunai undertakes no obligation to update these statements except as required by law..

这些声明基于当前的预期和假设，并受到可能致使实际结果产生重大差异的风险和不确定性的影响。Lunai 除法律要求外，没有义务更新这些声明。

SOURCE Lunai Bioworks Inc.

来源：Lunai生物工程公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示